Novo Nordisk has won the race to secure approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally. Jules Rimmer is a markets reporter in ...

Novo Nordisk first to market with Wegovy pill Analysts see potential but question if pills are a 'game changer' Advantage for Novo could be short-lived, analysts say The approval of Novo's Wegovy pill ...

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — ...

Dec 23 (Reuters) - Novo Nordisk shares jumped ‌10% on Tuesday after the U.S. Food and ‌Drug Administration approved its weight-loss pill, giving the Danish drugmaker a competitive edge over rival Eli ...

The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug. The Wegovy pill, as it’s called, is first oral version of a GLP-1 drug that ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making history again with the first FDA approval of a GLP-1 pill for weight loss.

FDA approves Novo Nordisk's weight-loss pill Novo aims to regain market share from Eli Lilly Pill broadens potential patient pool The pill is 25 milligrams of semaglutide, the same active ingredient ...

The pole position in the GLP-1 weight loss space is currently held by Eli Lilly. Novo Nordisk was the early leader, showing that being first doesn't always mean you stay at the head of the pack.

Novo Nordisk offers compelling value, trading at a 32% discount to fair value with a 3.6% yield and robust dividend growth. NVO's semaglutide-based drugs drive 74% of sales, but pipeline innovation, ...

Novo Nordisk NOVO.B1.08%increase; green up pointing triangle filed for U.S. Food and Drug Administration approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.

These two healthcare stocks are top names to invest in, but they haven't both been doing well of late. Eli Lilly has generated $25 billion in revenue from its fast-growing GLP-1 drugs this year. Novo ...

Every chief executive dreams of it: a product so successful that it propels their company from obscurity to superstardom seemingly overnight. Among the lessons from 2025, however, is that runaway ...